{"nctId":"NCT00353496","briefTitle":"Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours","startDateStruct":{"date":"2006-06"},"conditions":["Endocrine Tumors"],"count":264,"armGroups":[{"label":"lanreotide (Autogel formulation)","type":"EXPERIMENTAL","interventionNames":["Drug: lanreotide (Autogel formulation)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"lanreotide (Autogel formulation)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Endocrine tumour in the intestine or pancreas and with locally advanced or metastatic disease\n* No hormone related symptoms\n* Well or moderately differentiated tumour confirmed by histology\n* Tumour lesions which are measurable by a CT or MRI scan\n\nExclusion Criteria:\n\n* Previously treated with a somatostatin analogue unless more than 6 months ago and given for no more than 15 days\n* Treated within the last 6 months with interferon, chemoembolisation or chemotherapy or at any time with a radionuclide\n* Had a previous cancer except basal cell carcinoma and/or in situ carcinoma of the cervix/uterus and/or patients treated with curative intent and free from disease for 5 years\n* Pregnant or lactating\n* Females must use adequate contraception during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS)","description":"Time from randomization to first documentation of disease progression, or death. Disease progression centrally assessed using Response Evaluation Criteria in Solid Tumours (RECIST) v1.0","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Alive & Without Disease Progression","description":"Percentage of patients still ongoing (or completing at Week 96) without centrally assessed disease progression or death at Weeks 48 and 96.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Profile of Lanreotide","description":"Pharmacokinetic Profile of Lanreotide assessed by mean serum concentration at specified timepoints","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"0.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"0.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"0.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"0.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"0.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"0.39"}]}]}]},{"type":"SECONDARY","title":"Change in the Global Health Status Quality of Life Assessment","description":"Transformed scores from European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire responses (QLQ)-C30. Questionnaire response scores range from 0 to 100. Higher scores indicate best possible Quality of Life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.2","spread":"3.7"},{"groupId":"OG001","value":"-4.9","spread":"3.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With a Greater Than or Equal to 50% Decrease in Plasma Chromogranin A (CgA) Levels","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.2","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Still Alive Based on Available Overall Survival Data","description":"Overall survival defined as the time from randomisation to death due to any cause. Subjects were followed for overall survival beyond study completion/withdrawal via annual telephone contact until the last subject completed the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"77","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":101},"commonTop":["Diarrhoea","Abdominal pain","Nausea","Fatigue","Headache"]}}}